Results 351 to 360 of about 256,425 (387)
Some of the next articles are maybe not open access.
Antiplatelet drug nonresponsiveness
American Heart Journal, 2008The response to most medication, including antiplatelet drugs, is highly variable between individuals. Observational studies have shown that nonresponders to antiplatelet agents appear to have an increased incidence of vascular events. This review article reviews the background, mechanisms, and evidence in support of the clinical significance of this ...
Patrick, Gladding +4 more
openaire +2 more sources
American Heart Journal, 2010
Antiplatelet therapy is a cornerstone of the management of patients with acute coronary syndromes or for those undergoing percutaneous coronary intervention. As the intricacies of platelet biology and mechanisms of thrombus formation are revealed, novel antiplatelet therapies have emerged.
Michael A, Gaglia +2 more
openaire +2 more sources
Antiplatelet therapy is a cornerstone of the management of patients with acute coronary syndromes or for those undergoing percutaneous coronary intervention. As the intricacies of platelet biology and mechanisms of thrombus formation are revealed, novel antiplatelet therapies have emerged.
Michael A, Gaglia +2 more
openaire +2 more sources
Antiplatelet therapy – ticagrelor
Hämostaseologie, 2012SummaryTicagrelor, a cyclopentyltriazolopyrimidine (CPTP), is the representative of a new chemical class of P2Y12 receptor inhibitors that differ from thienopyridines (ticlopidin, clopidogrel, prasugrel) as ticagrelor is not a prodrug requiring active biotransformation by cytochromes in the liver and thus is characterized by a more rapid, more ...
E, Giannitsis, H A, Katus
openaire +2 more sources
Current Opinion in Hematology, 2009
Cardiovascular events are still a major concern despite dual antiplatelet treatment with aspirin and clopidogrel. Moreover, recent developments that improved platelet inhibition were associated with increased bleeding complications, suggesting that personal dose adjustment might be needed.
Galia, Spectre, David, Varon
openaire +2 more sources
Cardiovascular events are still a major concern despite dual antiplatelet treatment with aspirin and clopidogrel. Moreover, recent developments that improved platelet inhibition were associated with increased bleeding complications, suggesting that personal dose adjustment might be needed.
Galia, Spectre, David, Varon
openaire +2 more sources
Monitoring Antiplatelet Therapy
Seminars in Thrombosis and Hemostasis, 2017The increasing use of antiplatelet therapy, particularly aspirin and oral P2Y12 inhibitors, in the prevention and management of arterial thrombosis, has stimulated extensive pharmacodynamic studies and research into tailored antiplatelet regimens. Many different methodologies have been studied for monitoring antiplatelet drugs and some are now well ...
Rachel, Orme +2 more
openaire +2 more sources
Blood Reviews, 1997
Antiplatelet drugs are used in a wide range of disorders, either as sole agents or as adjuncts to other therapies. Aspirin has been shown to be clinically effective in a number of ischaemic conditions and has been in use for many years. The newer agents, ticlopidine and clopidogrel (which are thought to inhibit ADP-mediated platelet reactions) are also
J E, Joseph, S J, Machin
openaire +2 more sources
Antiplatelet drugs are used in a wide range of disorders, either as sole agents or as adjuncts to other therapies. Aspirin has been shown to be clinically effective in a number of ischaemic conditions and has been in use for many years. The newer agents, ticlopidine and clopidogrel (which are thought to inhibit ADP-mediated platelet reactions) are also
J E, Joseph, S J, Machin
openaire +2 more sources
Current Atherosclerosis Reports, 2011
Advances in antiplatelet therapy have significantly improved outcomes in patients with ischemic heart disease. Thienopyridines remain a cornerstone of therapy along with aspirin. Recently, concerns have been raised about the use of clopidogrel due to its pharmacokinetic and pharmacogenetic interpatient variability.
Luke, Kim +3 more
openaire +2 more sources
Advances in antiplatelet therapy have significantly improved outcomes in patients with ischemic heart disease. Thienopyridines remain a cornerstone of therapy along with aspirin. Recently, concerns have been raised about the use of clopidogrel due to its pharmacokinetic and pharmacogenetic interpatient variability.
Luke, Kim +3 more
openaire +2 more sources
Arteriosclerosis, Thrombosis and Vascular Biology, 2019
Current guidelines recommend dual antiplatelet therapy—a P2Y12 inhibitor (clopidogrel, prasugrel, or ticagrelor) and aspirin—for patients undergoing percutaneous coronary intervention. Although clopidogrel is the most commonly prescribed P2Y12 inhibitor,
Melissa D. Klein +3 more
semanticscholar +1 more source
Current guidelines recommend dual antiplatelet therapy—a P2Y12 inhibitor (clopidogrel, prasugrel, or ticagrelor) and aspirin—for patients undergoing percutaneous coronary intervention. Although clopidogrel is the most commonly prescribed P2Y12 inhibitor,
Melissa D. Klein +3 more
semanticscholar +1 more source
Current concepts and novel targets for antiplatelet therapy
Nature Reviews Cardiology, 2023M. Gawaz, T. Geisler, O. Borst
semanticscholar +1 more source
Perioperative antiplatelet therapy.
American family physician, 2010Aspirin is recommended as a lifelong therapy that should never be interrupted for patients with cardiovascular dis- ease. Clopidogrel therapy is mandatory for six weeks after placement of bare-metal stents, three to six months after myocardial infarction, and at least 12 months after placement of drug-eluting stents.
Chassot, P G +3 more
openaire +2 more sources